aTyr Pharma Secures $76,000,000 Series E Funding

  • Feed Type
  • Date
    4/1/2015
  • Company Name
    aTyr Pharma
  • Mailing Address
    3565 General Atomics Court San Diego, CA 92121 USA
  • Company Description
    We have developed proprietary methods for discovering Physiocrines, extracellular proteins that are derived from the tRNA synthetase family of enzymes, and which were predominantly overlooked by other genomic and secretome discovery efforts.
  • Website
    http://www.atyrpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $76,000,000
  • Transaction Round
    Series E
  • Proceeds Purposes
    The Company plans to use the proceeds to further develop its pipeline and advance its lead program through clinical trials, including an ongoing Phase 1b/2 trial of Resolaris, an investigational new drug representing aTyr’s first Physiocrine-based product candidate in the clinic.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy